1st Oct 2014 08:12
LONDON (Alliance News) - Hutchison China MediTech Ltd said Wednesday its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals has signed a co-promotion agreement with Merck Serono Co Ltd, a subsidiary of the US's Merck & Co Inc.
Under the agreement Hutchison will exclusively co-promote Merck Serono's cardiovascular drug bisoprolol fumarate under the trademark Concor in China.
Hutchison has a commercial network of around 1,600 cardiovascular market focused sales representatives covering more than 13,000 hospitals, it said.
No financial details of the agreement were disclosed.
Shares in Hutchison China MediTech were trading flat at 1,190.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed